prostate tumor antigen-activated autologous dendritic cell vaccine

A dendritic cell (DC)-based cancer vaccine composed of autologous dendritic cells (DCs) activated with a prostate tumor cell lysate containing tumor-associated antigens (TAAs) with potential immunostimulatory and antineoplastic activities. Upon administration, the prostate tumor antigen-activated autologous DC vaccine may stimulate an anti-tumoral cytotoxic T-lymphocyte (CTL) response against prostate cancer cells expressing prostate tumor cell-specific antigens, which may result in prostate tumor cell lysis. Check for active clinical trials using this agent. (NCI Thesaurus)

Related Posts

Award Winning Physicians

Our Physicians work for you, ensuring the highest standard of care.

Learn More